C-reactive protein reduction post treatment is associated with improved survival in atezolizumab tre...
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab treated non-small cell lung cancer patients
About this item
Full title
Author / Creator
Publisher
Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
Public Library of Science
Subjects
More information
Scope and Contents
Contents
Overall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum C-reactive protein (CRP) in non-small cell lung cancer (NSCLC) trials with atezolizumab (anti-PD-L1) as an early OS surrogate. Serum from patients enrolled in randomized Phase II (n = 240) and Pha...
Alternative Titles
Full title
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab treated non-small cell lung cancer patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A650617173
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A650617173
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0246486
